Focused Cancer Updates: Neoadjuvant Therapy for Breast Cancer and Managing Immunotherapy Toxicity

An expert panel delivers news to inform therapy and monitoring decisions, including a look at how the I-SPY 2 trial is accelerating evaluation of promising agents in high-risk breast cancer (as well as cutting down on unlikely-to-help treatments); opportunities to reduce late recurrence in patients with HR-positive tumors; better ways to address immunotherapy's toxic effects in survivors, part of the mission of UCSF's new CITE (Cancer Immunotherapy Toxicity Evaluation) Program; and immediate steps to take when cancer survivors present with fatigue, thirst or other hormonal symptoms.